TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03166189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow-derived MSC and HRT
Description: * Transplantation procedure to endometrial cavity is performed with ultrasound guidance on menstrual cycle day 5-6 through uterine cervix using cater for embryo transfer with 1 ml of suspension containing 5 millions of autologous bone marrow-derived mesenchymal stem cells~* Three cycles of HRT following MSC transplantation;~* Pipelle-biopsy of endometrium on day 20 of hormonal replacement therapy of the last (third) cycle;~* Frozen/thawed embryo transfer 3-6 months after transplantation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hormonal replacement therapy
Description: standard treatment of hypoplastic endometrium or Asherman's syndrome:~* Three cycles of HRT preceding frozen/thawed embryo transfer;~* Frozen/thawed embryo transfer.
Study: NCT01051856

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SEAMGUARD with bioabsorbable staple
Description: In the SEAMGUARD group, pancreatic resection and transection of the pancreatic body will be executed using an endoscopic linear stapling device.
Study: NCT02270762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest in bed
Study: NCT01997814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: herbal immunomodulator
Description: Patients in Test Group were treated with scaling and root planing (SRP) along with Herbal Immunomodulators (Septilin) therapy, 2 tablets twice daily for 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in Control Group were treated with scaling and root planing (SRP) along with Placebo therapy, 2 tablets twice daily for 3 weeks.
Study: NCT00681564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-Stage Full-Mouth Disinfection
Description: * Scaling and root planing, four quadrants in one session~* Tongue brushing with a 1% chlorhexidine gel (1 minute)~* Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes)~* Subgingival chlorhexidine (1%) irrigation in all pockets~* Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention~* Basic oral hygiene instructions~* Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal care
Description: * Basic oral hygiene instructions~* Supragingival plaque removal
Study: NCT04039607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive nivolumab as intravenous (IV) infusion.
Study: NCT04511598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bellus 3D Face Camera
Description: The depth sensor uses infrared structured light scanning technology to capture depth and the camera on the phone or tablet to capture color texture of the face.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bellus 3D Face Camera
Description: The depth sensor uses infrared structured light scanning technology to capture depth and the camera on the phone or tablet to capture color texture of the face.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Planmeca ProMax 3D Proface
Description: The lasers scan the facial geometry and the digital cameras capture the color texture of the face.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Planmeca ProMax 3D Proface
Description: The lasers scan the facial geometry and the digital cameras capture the color texture of the face.
Study: NCT01051856

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TissueLink with radiofrequency ablation
Description: After pancreatic transection with the method of choice of the operating surgeon, the pancreatic remnant will be treated with Tissuelink alone for an ablation depth (thickness) of approximately 7 mm.
Study: NCT03137433

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal-replacement Therapy
Description: We seek to examine the effect of meal-replacement therapy on weight loss outcomes in teens with severe obesity.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal-replacement Therapy
Description: We seek to examine the effect of meal-replacement therapy on weight loss outcomes in teens with severe obesity.
Study: NCT04755699

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Stimulation
Description: The study involves the administration of various electrical pulses being delivered to muscles and/or the spinal column with an investigational neurostimulator to evoke various limb movements in order to improve functional movement.
Study: NCT04231539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Vape different flavor nicotine products

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Vape different flavor nicotine products

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaporizer Device
Description: Take puffs from vaporizer filled with different flavors

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaporizer Device
Description: Take puffs from vaporizer filled with different flavors
Study: NCT00422591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1.5 g/m2 IV over 24 hours daily on day 1-4 (age \<60 years) or days 1-3 (age \> 60 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 12 mg/m2 IV over 1 hour daily x 3 (days 1-3)
Study: NCT03680950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper Gastrointestinal Monitoring System
Description: Participants will wear a monitoring system consisting of a tiny endoscopy and a mobile device. The endoscopy is inserted to upper gastrointestinal tract via nasal cavity and the mobile device is set to take and send images from the endoscopy to a server for analyzing if the abnormal condition occurs.
Study: NCT01729507

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Stimulation will be performed with a DC stimulator MC Location of stimulation: Anode over the left dorsolateral cortex, corresponding with F3 (in 10-20 EEG system); cathode over the right temporal cortex Intensity: 2 mA Total duration: Constant stimulation for 20 minutes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: standardised behavioural therapy
Description: The standardised behavioural therapy will be performed according to the certified Smoke-free programme' of the of the Institute for Therapy Research ('Institut für Therapieforschung', IFT). The course leaders' manual specifies that the ideal number of participants is 8-12.~1 group session for 90 minutes/week for 7 weeks, 2 telephone calls of 10 minutes each, first after the fourth session 3 days after collective smoking cessation, second on day 3 after the last session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standardised behavioural therapy
Description: The standardised behavioural therapy will be performed according to the certified Smoke-free programme' of the of the Institute for Therapy Research ('Institut für Therapieforschung', IFT). The course leaders' manual specifies that the ideal number of participants is 8-12.~1 group session for 90 minutes/week for 7 weeks, 2 telephone calls of 10 minutes each, first after the fourth session 3 days after collective smoking cessation, second on day 3 after the last session.
Study: NCT05545254

Intervention type: GENETIC
Intervention: genetic testing
Description: Two questionnaires were included in the link, one referring to the demographic information, and another one involving the health-promoting lifestyle. In the demographic information, the genetic test results were not requested to be written, but the participants need to answer whether they understand the results. The HPLP-Ⅱ is an scale instrument used to evaluate a person's health-promoting lifestyle behaviors, which contains 52 items and has been translated into Chinese in 1997. It contains 6 subscales: self-actualization, health responsibility, physical activity, nutrition, interpersonal relationships and stress management.
Study: NCT02985164

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PDSa
Description: After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSa1 (outside lead apron),PDSa2 (inside lead apron).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PDSb
Description: After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSb1 (outside lead apron), PDSb2 (inside lead apron).
Study: NCT00495170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 2 area under curve (AUC) by vein Weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiotherapy
Description: 2 GY/fraction for 37 fractions (daily treatment, Monday to Friday, for 7.5 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m\^2 by vein Weekly
Study: NCT04755699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Stimulation
Description: The study involves the administration of various electrical pulses being delivered to muscles and/or the spinal column with an investigational neurostimulator to evoke various limb movements in order to improve functional movement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Stimulation
Description: The study involves the administration of various electrical pulses being delivered to muscles and/or the spinal column with an investigational neurostimulator to evoke various limb movements in order to improve functional movement.
Study: NCT04188522

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetoencephalography (MEG)
Description: Participants will undergo MEG at the University of Maryland (College Park) to measure cerebral activity while performing a visual naming task. The Montreal Cognitive Assessment (MOCA) will also be administered.
Study: NCT03437031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality device
Description: For those patients randomized to VR, the study staff member will explain the use of the Samsung VR goggle set, and thereafter will allow the patient to use the device freely for up to 30 minutes. Intervals of 2-5 minutes is suggested for first-time use, and patients will be to allowed to discontinue it at any time as long as they are not experiencing any discomfort or side effects (dizziness, motion sickness, etc.). The study staff member will be present at all times, and will work with hospital staff as necessary to ensure the patient is receiving appropriate clinical care throughout the duration of the intervention.
Study: NCT03229135

Intervention type: DEVICE
Intervention: other antibacterial agents，breathing machine
Description: If treatment failure for patients in group A，group B，group C and group D，change dose of teicoplanin or other antibacterial agents. Mechanical ventilation was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of teicoplanin therapy.
Study: NCT03078647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profound
Description: The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
Study: NCT03229135

Intervention type: DEVICE
Intervention: other antibacterial agents，breathing machine
Description: If treatment failure for patients in group A，group B，group C and group D，change dose of teicoplanin or other antibacterial agents. Mechanical ventilation was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of teicoplanin therapy.

Intervention type: DEVICE
Intervention: other antibacterial agents，breathing machine
Description: If treatment failure for patients in group A，group B，group C and group D，change dose of teicoplanin or other antibacterial agents. Mechanical ventilation was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of teicoplanin therapy.

Intervention type: DEVICE
Intervention: other antibacterial agents，breathing machine
Description: If treatment failure for patients in group A，group B，group C and group D，change dose of teicoplanin or other antibacterial agents. Mechanical ventilation was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of teicoplanin therapy.
Study: NCT03516513

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy as Usual
Description: Treatment as usual to deliver 6 weekly sessions to teach patients how to use the seven step process to solve problems.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assisted Problem Solving Therapy
Description: Smart note assisted delivery of 6 weekly session to teach patients how to use the seven step process to solve problems
Study: NCT05805982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: Pre-recorded educational video including hereditary cancer information, genetic cancer testing candidates, types of testing, type of results, benefits and risks, recommendations according to results, inheritance and common questions.
Study: NCT04223375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Training
Description: Postpartum women were educated on postpartum healthy and regular nutrition.
Study: NCT04128501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT01307748

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: aroma
Description: Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
Study: NCT05805982

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In person genetic cancer counseling
Description: Includes:~Family history of cancer (3-generation family tree) Personal Cancer Risk Assessment Education on inheritance and expression of disease Types of tests Preparation on possible outcomes according to results Obtaining consent for test Opportunity to solve doubts
Study: NCT01307748

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: aroma
Description: Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aroma
Description: Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
Study: NCT02286258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium EDTA
Description: Calcium EDTA for equilibrium GFR measurement : bolus injection 30 mg/kg, then 10 mg/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Calcium EDTA for single injection GFR measurement : bolus injection depending on the estimated GFR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gd-DOTA
Description: Gd-DOTA for equilibrium GFR measurement : bolus injection 56 ng/kg, then 28 ng/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Gd-DOTA for single injection GFR measurement : bolus injection depending on the estimated GFR
Study: NCT03616145

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: Experimental Condition

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light Touch
Description: Comparator Arm
Study: NCT02441660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% Patch
Description: Applied topically for 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% Patch
Description: Applied topically for 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Capsaicin 0.025% Well Patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Capsaicin 0.025% Well Patch
Study: NCT03173599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA 40mg
Description: The beginning dose is 40mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA 80mg
Description: The single dose is 80mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA 160mg
Description: The single dose is 160mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA 240mg
Description: The single dose is 240mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA 360mg
Description: The single dose is 360mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA 480mg
Description: The single dose is 480mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PNA Placebo
Description: The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg.
Study: NCT01454869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).
Study: NCT01116297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging with S-FLARE imaging system
Description: Tissue oxygenation measurements during plastic surgery using the S-FLARE system.
Study: NCT03035708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 1 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 1 mg BID
Study: NCT01199523

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: oral
Study: NCT00795756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposome-encapsulated cytarabine (DepoCyte)
Description: DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple intrathecal therapy (TIT)
Description: Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
Study: NCT03084874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity and sedentary behavior coaching program
Description: The intervention group will receive an individualized coaching program. During a motivational interview an experienced physiotherapist will asses participant's usual exercise habits, possible barriers and facilitators, self-efficacy and motivation to increase physical activity and reduce sedentary time. Based on these data (and baseline physical activity/sedentary information) an individualized, progressive program with specific goals setting and self-monitoring will be established (patients will be active participants and decision makers in this process).
Study: NCT01928329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide (Bydureon®)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01637467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Description: EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham EMS
Description: Sham EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
Study: NCT01065233

Intervention type: GENETIC
Intervention: DNA extraction
Description: DNA extraction of blood sample for DNAship analysis

Intervention type: GENETIC
Intervention: DNA extraction
Description: DNA extraction of blood sample for DNAship analysis
Study: NCT03611790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeVa VS
Description: mechanical dilatation
Study: NCT02136186

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philips Telehealth
Description: patients will be provided with a philips home telemonitoring system post hospital discharge
Study: NCT00697203

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: 40mg po daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: 40mg po daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: 40mg po daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pravastatin
Description: 40mg po daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Description: 300mg po daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Description: 600mg po daily for 12 weeks
Study: NCT01240785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
Study: NCT00258115

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: salsalate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salsalate